A detailed history of Woodline Partners LP transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Woodline Partners LP holds 709,831 shares of SRRK stock, worth $29.3 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
709,831
Previous 708,187 0.23%
Holding current value
$29.3 Million
Previous $5.9 Million 3.63%
% of portfolio
0.05%
Previous 0.06%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.63 - $9.71 $12,543 - $15,963
1,644 Added 0.23%
709,831 $5.69 Million
Q2 2024

Aug 14, 2024

SELL
$7.84 - $16.79 $2.77 Million - $5.94 Million
-353,563 Reduced 33.3%
708,187 $5.9 Million
Q1 2024

May 15, 2024

BUY
$13.2 - $17.76 $1.81 Million - $2.43 Million
136,867 Added 14.8%
1,061,750 $18.9 Million
Q4 2023

Feb 14, 2024

BUY
$6.52 - $20.32 $2.67 Million - $8.32 Million
409,267 Added 79.37%
924,883 $17.4 Million
Q3 2023

Nov 14, 2023

BUY
$6.02 - $7.76 $127,316 - $164,116
21,149 Added 4.28%
515,616 $3.66 Million
Q2 2023

Aug 14, 2023

BUY
$5.79 - $9.11 $2.86 Million - $4.5 Million
494,467 New
494,467 $3.73 Million
Q4 2021

Feb 14, 2022

SELL
$24.14 - $35.18 $3.29 Million - $4.8 Million
-136,359 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$26.34 - $46.62 $41,037 - $72,633
-1,558 Reduced 1.13%
136,359 $3.94 Million
Q1 2021

May 17, 2021

BUY
$45.96 - $68.02 $67,055 - $99,241
1,459 Added 1.07%
137,917 $6.99 Million
Q4 2020

Feb 16, 2021

BUY
$13.72 - $51.57 $1.87 Million - $7.04 Million
136,458 New
136,458 $6.62 Million

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.13B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.